Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds

Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds

291305

Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds

Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS) patients switching treatment, according to the latest Spherix Global Insights’ report. The launch of MS generics, bioequivalents, and new brands in the U.S. market over the past year has increased competition and promoted “an active switching dynamic,” with patients starting on a new disease-modifying therapy (DMT) “in hopes of an improved outcome,” a Spherix press release summarizing…

You must be logged in to read/download the full post.